Clinical characteristics of the VITT-positive and VITT-negative patient population in Canada
| Patient demographics . | VITT-positive (n = 43) . | VITT-negative (n = 113) . | Significance (P value) . |
|---|---|---|---|
| Female (%) | 21/43 (48.8%) | 51/113 (45.1%) | .680 |
| Median age (range), y | 52 (29-73) | 61 (19-82) | <.001* |
| Median days to symptom onset post-vaccine (range) | 15 (7-61) | 25 (4-92) | <.001* |
| Heparin treatment | 0/38 (0.0%)† | 3/103 (2.9%)† | .290 |
| Vaccine type | |||
| ChAdOx1 nCoV-19 (AstraZeneca) | 40/43 (93.0%) | 89/113 (78.8%) | .037 |
| Ad26.COV2.S (Johnson & Johnson) | 2/43 (4.7%) | 1/113 (0.9%) | .126 |
| BNT162b2 (Pfizer-BioNTech) | 1/43 (2.3%) | 14/113 (12.4%) | .057 |
| mRNA-1273 (Moderna) | 0/43 (0.0%) | 9/113 (7.9%) | .059 |
| Clinical presentation | |||
| Total thrombocytopenia (<150 × 109/L) | 32/35 (92.4%)† | 55/93 (59.1%)† | <.001 |
| Total thrombosis | 38/39 (94.9%)† | 63/99 (63.6%)† | <.001 |
| Thrombocytopenia and thrombosis | 30/35 (85.7%)† | 27/91 (29.7%)† | <.001 |
| Thrombocytopenia alone | 2/35 (5.7%)† | 27/91 (29.7%)† | .004 |
| Thrombosis alone | 3/35 (8.6%)† | 30/91 (33.0%)† | .006 |
| Thrombotic manifestations‡ | |||
| CVST | 14/38 (36.8%)† | 3/63 (4.8%)† | <.001 |
| DVT | 9/38 (23.7%)† | 24/63 (38.2%)† | .135 |
| PE | 12/38 (31.6%)† | 20/63 (31.7%)† | .986 |
| Other (ie, acute arterial clot, portal vein thrombosis, stroke) | 14/38 (36.8%)† | 19/63 (30.2%)† | .488 |
| Immunoassay results | |||
| IgG/A/M-EIA, mean OD405nm (range) | 2.20 (0.62-3.35) | 0.74 (0.06-1.09) | <.001 |
| PF4-EIA mean OD405nm (range) | 2.10 (0.88-3.76) | 0.75 (0.07-0.71) | <.001 |
| PF4/heparin-EIA, mean OD405nm (range) | 1.67 (0.75-3.49) | 0.64 (0.62-0.65) | <.001 |
| Patient demographics . | VITT-positive (n = 43) . | VITT-negative (n = 113) . | Significance (P value) . |
|---|---|---|---|
| Female (%) | 21/43 (48.8%) | 51/113 (45.1%) | .680 |
| Median age (range), y | 52 (29-73) | 61 (19-82) | <.001* |
| Median days to symptom onset post-vaccine (range) | 15 (7-61) | 25 (4-92) | <.001* |
| Heparin treatment | 0/38 (0.0%)† | 3/103 (2.9%)† | .290 |
| Vaccine type | |||
| ChAdOx1 nCoV-19 (AstraZeneca) | 40/43 (93.0%) | 89/113 (78.8%) | .037 |
| Ad26.COV2.S (Johnson & Johnson) | 2/43 (4.7%) | 1/113 (0.9%) | .126 |
| BNT162b2 (Pfizer-BioNTech) | 1/43 (2.3%) | 14/113 (12.4%) | .057 |
| mRNA-1273 (Moderna) | 0/43 (0.0%) | 9/113 (7.9%) | .059 |
| Clinical presentation | |||
| Total thrombocytopenia (<150 × 109/L) | 32/35 (92.4%)† | 55/93 (59.1%)† | <.001 |
| Total thrombosis | 38/39 (94.9%)† | 63/99 (63.6%)† | <.001 |
| Thrombocytopenia and thrombosis | 30/35 (85.7%)† | 27/91 (29.7%)† | <.001 |
| Thrombocytopenia alone | 2/35 (5.7%)† | 27/91 (29.7%)† | .004 |
| Thrombosis alone | 3/35 (8.6%)† | 30/91 (33.0%)† | .006 |
| Thrombotic manifestations‡ | |||
| CVST | 14/38 (36.8%)† | 3/63 (4.8%)† | <.001 |
| DVT | 9/38 (23.7%)† | 24/63 (38.2%)† | .135 |
| PE | 12/38 (31.6%)† | 20/63 (31.7%)† | .986 |
| Other (ie, acute arterial clot, portal vein thrombosis, stroke) | 14/38 (36.8%)† | 19/63 (30.2%)† | .488 |
| Immunoassay results | |||
| IgG/A/M-EIA, mean OD405nm (range) | 2.20 (0.62-3.35) | 0.74 (0.06-1.09) | <.001 |
| PF4-EIA mean OD405nm (range) | 2.10 (0.88-3.76) | 0.75 (0.07-0.71) | <.001 |
| PF4/heparin-EIA, mean OD405nm (range) | 1.67 (0.75-3.49) | 0.64 (0.62-0.65) | <.001 |